Australia markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3300+0.0100 (+0.76%)
At close: 04:00PM EDT
1.3500 +0.02 (+1.50%)
After hours: 07:20PM EDT

Geron Corporation

919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 69

Key executives

NameTitlePayExercisedYear born
Dr. John A. Scarlett M.D.Chairman, Pres & CEO1.26MN/A1951
Ms. Olivia Kyusuk BloomExec. VP of Fin., CFO & Treasurer743.27kN/A1969
Dr. Andrew J. GrethleinExec. VP & COO767.28kN/A1964
Ms. Melissa A. Kelly BehrsExec. VP of Bus. Operations & Chief Alliance Officer753.22kN/A1964
Dr. Aleksandra Rizo M.D., Ph.D.Exec. VP & Chief Medical Officer866.73kN/A1975
Mr. Anil KapurExec. VP of Corp. Strategy & Chief Commercial Officer654.89kN/A1970
Ms. Suzanne MessereHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Stephen N. Rosenfield J.D.Exec. VP, Chief Legal Officer & Corp. Sec.N/AN/A1950
Ms. Shannon OdamVP of HRN/AN/AN/A
Mr. Edward E. KovalExec. VP & Chief Bus. OfficerN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Corporate governance

Geron Corporation’s ISS governance QualityScore as of 1 May 2022 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.